Purchase this article with an account.
V. Touitou, M. A. Johnson, N. R. Miller, Y. Guo, D. Bernstein, S. L. Bernstein; Sustained Neuroprotection After a Single Intravitreal Injection of PGJ2 in a Rodent Model of NAION. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3838.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Prostaglandin J2 (PGJ2) has been proposed as a potential neuroprotective agent. We wanted to evaluate the toxicity and the efficacy of a single intravitreal (IVT) injection of PGJ2 in a rodent model of nonarteritic anterior ischemic optic neuropathy (NAION).
We used the laser-activated rose Bengal induction method to produce NAION in Long-Evans rats. We also evaluated IVT-PGJ2 retinal toxicity. Following induction, PGJ2 was intravitreally injected in the treatment group. IVT phosphate buffered saline (PBS) was used as a control. Functional studies (VEP) were performed at baseline and at 7 days post-treatment to assess retinal and axonal status. Structural studies included immunohistochemical (IHC) and electron microscopic (EM) analysis of the optic nerve (ON), and stereologic analysis of changes in retinal ganglion cell (RGC) numbers 30 days post-induction.
A single IVT injection of PGJ2 produces no evidence of retinal or ON toxicity by either functional or structural analysis in healthy adult rats. The intravitreal route of administration enables delivery of a high concentration of the drug in a low volume, with minimal risks from systemic side effects. Additionally, a single IVT injection of PGJ2 preserved RGCs and their axons and provided sustained neuroprotection for at least 1 month following the initial ischemic event in a rodent model of NAION. Ongoing studies are being conducted to evaluate whether a similar effect is observed in primates.
This PDF is available to Subscribers Only